Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Cardiovasc; Carmen; Corifeo; Lercadip; Lercapdip; Lerdip; Lerez; Lerka; Lerzam; R 75; REC 152375; TJN 324; Vasodip; Zanedip; Zanidip

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Recordati
  • Developer A.R. Kamm Associates; Algorithm; Andromaco; Dexcel-Pharma; Digital Gene Technologies; Elmor; Fako Ilaclari; Forest Laboratories; Fournier Pharma Inc; Gador; Grunenthal; Himont Pharmaceutical; Laboratoires Fournier; Laboratorios Sanfer; LG Chem; Meda; Orient Europharma; Recordati; Robapharm; Solvay; UCB; Zuoz Pharma
  • Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top